African Journal of Traditional, Complementary and Alternative Medicines
African Ethnomedicines Network
Vol. 11, No. 5, 2014, pp. 16-27
Bioline Code: tc14140
Full paper language: English
Document type: Research Article
Document available free of charge
African Journal of Traditional, Complementary and Alternative Medicines, Vol. 11, No. 5, 2014, pp. 16-27
© Copyright 2014 - African Journal of Traditional, Complementary and Alternative Medicines
BENEFICAL THERAPEUTIC EFFECT OF CHINESE HERBAL XINJI'ERKANG FORMULA ON HYPERTENSION-INDUCED RENAL INJURY IN THE 2-KIDNEY-1-CLIP HYPERTENSIVE RATS|
Huang, Ling-ling; Pan, Chen; Yu, Ting-ting; Guo, Kun; Wang, Xing-hui; Zhang, Jun-Yan; Wang, Hong-zhi & Gao, Shan
Background: Increase in evidence shows that the role of kidney injury in hypertension is important. Xinji'erkang (XJEK), a Chinese herbal
formula, has been identified as an effective preparation in the treatment of coronary heart disease and myocarditis. We have previously
demonstrated that XJEK attenuate oxidative stress and hypertension target organ damage. The aim of this study was to assess the renal protective
function of XJEK.
Materials and Methods: Two Kidney One Clip (2K1C) model was adopted to induce hypertension in rats. We submitted male Sprague Dawley
(150-180) g rats to either renal artery clipping or sham operation. Renal hypertension was established after four weeks of surgery. Rats were
randomized divided into the four groups: sham-operated group (Sh-Op) (n=10), two-kidney, one-clip hypertension group (2K1C) (n=10),
Xinji'erkang treatment group (XJEK) (n=10) and Fosinopril (n=10) treatment group. Drugs were administered orally daily for four weeks.
Systolic pressures were measured every week using the tail-cuff apparatus. 24h before death, urine samples were collected for detect of urinary
proteins. The kidney weight (KW) index was expressed as kidney weight/body weight (KW/BW). The histological changes were investigated by
hematoxylin and eosin and Van Gieson staining. Immunohistochemical assay was employed to observe the intra-renal transforming growth
factor-β1 (TGF-β1) protein expression. Serum creatinine (SCR) and blood urea nitrogen (BUN) were assayed by automatic biochemical analyzer.
ELISA kit was used to assay Angiotensin II (Ang II) and TGF-β1 content in serum.
Results: Administration of XJEK markedly alleviated the rise in blood pressure and declined LKW/BW ratio. Histo-pathological injuries
including hypertrophic glomerular, glomerular sclerosis, glomerular and interstitial fibrosis were attenuated. XJEK also decreased SCR, BUN,
urinary proteins in 24h urine, serum Ang II and TGF-β1 concentrations and the intra-renal TGF-β1 protein expression.
Conclusion: XJEK therapy in the 2K1C hypertensive rats affects the rise in blood pressure and ameliorates the severity of kidney injury. The
protective effect is most likely due to the ability of XJEK to affect the Renin-Angiotensin-Aldosterone System (RAAS) and the TGF-β systems.
renal injury; 2K1C hypertensive; Xinji'erkang (XJEK) formula; transforming growth factor-β1 (TGF-β1); Angiotensin II (Ang II)
Alternative site location: http://journals.sfu.ca/africanem/index.php/ajtcam